References
- Crosby RD, Kolotkin RL, Williams GR Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(5):395–407.
- Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–109.
- McLeod LD, Coon CD, Martin SA, et al. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(2):163–169.
- Shields AL, Coon C, Hao Y, et al. Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods. Expert Rev Pharmacoeconomics Outcomes Res. 2015;15(6):951–959.
- Wyrwich KW, Norquist JM, Lenderking WR, et al. Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. 2013;22(3):475–483.
- Food and Drug Administration. Patient reported outcome measures: use in medical product development to support labeling claims. 2009. [cited 2018 Aug 13]. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/UCM193282.pdf.
- Uryniak T, Chan ISF, Fedorov VV, et al. Responder analyses — a PhRMA position paper. Stat Biopharm Res. 2011;3(3):476–487.
- The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
- Feng Y, Parkin D, Devlin NJ Assessing the performance of the EQ-VAS in the NHS PROMs programme. Qual Life Res. 2014;23(3):977–989.
- Szende A, Janssen B, Cabases J Self-reported population health: an international perspective based on EQ-5D. Netherlands: Springer; 2014
- Badia Llach X, Herdman M, Schiaffino A Determining correspondence between scores on the EQ-5D “thermometer” and a 5-point categorical rating scale. Med Care. 1999;37(7):671–677.
- Pickard AS, Neary MP, Cella D Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
- Nolan CM, Longworth L, Lord J, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016; 71 493–500
- Zanini A, Aiello M, Adamo D, et al. Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respir Care. 2015;60(1):88–95
- Feng Y, Herdman M, Van Nooten F, et al. An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. Qual Life Res. 2017;26:2067–2078.
- Junghaenel DU, Broderick JE, Schneider S, et al. Applied Research Quality Life. 2018;13(3):585–601. https://doi.org/10.1007/s11482-017-9546-3